Juan Montoro, Diderik-Jan Eikema, Joe Tuffnell, Victoria Potter, Krzysztof Kałwak, Constantijn Jm Jm Halkes, Alexander Kulagin, Matthew Collin, Robert F Wynn, Stephen Robinson, Emma Nicholson, Henrik Sengeloev, Khalid Halahleh, Elena Skorobogatova, Jaime Sanz, Jakob R Passweg, Stephan Mielke, Samppa Johannes Ryhänen, Ben Carpenter, Tobias Gedde-Dahl, Eleni Tholouli, Renato Fanin, Philippe Lewalle, Austin G Kulasekararaj, Antonio Maria Risitano, Régis Peffault de Latour
Selecting the most suitable alternative donor becomes challenging in severe aplastic anemia (SAA) when a matched sibling donor (MSD) is unavailable. We compared outcomes in SAA patients undergoing SCT from matched unrelated donors (MUD, n=1106), mismatched unrelated donors (MMUD, n=340), and haploidentical donors (Haplo, n=206) registered in the EBMT database (2012-2021). For Haplo-SCT, only those receiving post-transplant cyclophosphamide (PT-Cy) for graft-versus-host disease (GVHD) prophylaxis were included...
April 21, 2024: Blood